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1Washington University
Journal of Law and Policy
Patent Law and Policy Symposium
Re-Engineering Patent Law: The Challenge
of New Technologies
Introduction
Charles R. McManis*
The constitutionally mandated purpose of the U.S. patent
system is to promote the progress of “useful Arts”1— or in more
modern parlance, to promote technological innovation.2
Congress is empowered to accomplish this purpose by securing
for limited times to inventors the exclusive right to their
discoveries. However, to ensure that the grant of exclusive
patent rights does in fact promote— rather than retard—
technological innovation, each of the institutional actors in the
U.S. patent system— Congress, the courts, and the U.S. Patent
and Trademark Office— must perennially balance the need to
provide inventors with adequate incentives to innovate against
the public interest in having access to and fostering a
* Professor of Law, Washington University.
1. The U.S. Constitution, art. I, § 8, cl. 8, empowers Congress to “promote the Progress
of Science and useful Arts, by securing for limited Times to Authors and Inventors the
exclusive Right to their respective Writings and Discoveries . . . .”
2. See In re Bergy, 596. F.2d 952, 959 (1979) (citing In re Musgrave, 431 F.2d 882, 893
(1970) for the proposition that “the present day equivalent of the term ‘useful arts’ employed by
the Founding Fathers is ‘technological arts’”).
Washington University Open Scholarship
227.doc 08/24/00
2 Re-Engineering Patent Law [Vol. 2:1
competitive marketplace for innovations.
As the title of this symposium issue of the Washington
University Journal of Law and Policy suggests, new
technologies inevitably play as pivotal a role in shaping the
development of patent policy as the patent system plays in the
development of new technologies— though not always with
salutary results or to universal applause. One need only consult
the day’s headlines to make the point. For example, in the short
space of two weeks preceding the conference at which the
papers included in this symposium were presented, not one but
two separate news articles railed against what the headlines of
both declared to be “patently absurd” claims contained in
patents recently issued by the U.S. Patent and Trademark
Office (PTO).3 Just one week before the conference, National
Public Radio aired an hour-long segment of its popular “Talk of
the Nation: Science Friday” program, which was devoted
entirely to the two new technologies spawning all the
headlines— namely digital technology and biotechnology— and
featured among other guests one of the three scheduled keynote
speakers for the conference, then Commissioner, now Director
of the PTO, Q. Todd Dickinson.4
The challenge posed by these two new technologies
implicates some of the fundamental premises of patent law. For
3. See James Gleik, Patently Absurd, N.Y. TIMES, Mar. 12, 2000, (magazine) at 44;
Randall E. Stross, Patently Absurd Claims: Clueless Courts and a Broken Patent System Help
Amazon, U.S. NEWS & WORLD REP., Mar. 20, 2000, at 56 (reporting on the issuance of U.S.
Patent No. 5,960,411, “Method and system for placing a purchase order via a communications
network”— better known as Amazon.com’s patented One Click® feature).
4. See Science Friday, March 24, 2000: Hour One: Technology Patents, (visited Apr.
13, 2000) (NPR radio broadcast, Mar. 24, 2000) <http://www.sciencefriday.com/pages/2000/
mar/hour1_032400.html>. On March 29, 2000, just two days before the conference,
Commissioner Dickinson’s title was changed to Under Secretary of Commerce for Intellectual
Property and Director of the United States Patent and Trademark Office, pursuant to the
American Inventors Protection Act of 1999, which was enacted as Title IV-Inventor Protection
of the Intellectual Property and Communications Omnibus Reform Act of 1999, P.L. 106-113.
The title change was a part of a larger effort to transform the PTO into a “performance-based
organization.” See generally Sabra Chartrand, What’s in a Name? A Sign of Other Changes at
the United States Patent and Trademark Office, N.Y. TIMES, Apr. 3, 2000, at C6.
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example, patent protection for inventions has been held to
exclude any protection for abstract ideas, natural laws or
principles, and phenomena of nature.5 For a time, courts also
purported to exclude business methods from the subject matter
of protection.6 Today, however, inventors of software-related
inventions have come perilously close to obtaining patents on
mathematical algorithms, or at least on the use of certain
algorithms for particular purposes.7 Likewise, biotechnology
patents have come very close to claiming phenomena of
nature— namely, isolated genetic sequences.8 And, in a recent
case, State Street Bank & Trust Co. v. Signature Financial
Group,9 the Court of Appeals for the Federal Circuit (CAFC),
the federal court specializing in patent appeals, held that there
was no business methods exception to the patentability of
processes and upheld a patent for a computerized data
processing system for a “hub and spoke” financial services
configuration for managing mutual funds.10
The result has been what one paper in this symposium calls
“the patent gold gush,” in which “inventions long thought
unpatentable— everything from gene sequences of unknown
function to one-step purchasing over the Internet— are now
being claimed as property.”11 These developments are of
particular concern because they tend to allow patents on subject
matter that is both further “upstream” in the innovation process
and further afield from traditional industrial products and
processes than has ever before been the case. As the subject
5. See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (noting that “laws of nature,
physical phenomena, and abstract ideas have been held not patentable”).
6. See generally 1 DONALD S. CHISUM, CHISUM ON PATENTS § 1.03[5] (1999).
7. See, e.g., In re Alappat, 33 F.3d 1526, 1545 (Fed. Cir. 1994) (Archer dissenting).
8. See, e.g., Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd., 927 F.2d 1200, 1204 (Fed.
Cir. 1991) (involving a patent claim to “a purified and isolated DNA sequence consisting
essentially of a DNA sequence encoding human erythropoietin”).
9. 149 F.3d 1368 (Fed. Cir. 1998).
10. Id. at 1375.
11. See Arti Rai, Addressing the Patent Gold Rush: The Role of Deference to PTO Patent
Denials, 2 WASH. U. J.L. & POL’Y 199 (2000).
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matter of patent protection expands both upstream to basic
research in new technology fields and outward from industrial
to business methods, two fundamental questions arise: 1)
whether the incentive of patent protection is really necessary to
stimulate such innovation; and 2) whether the grant of such
patent protection will, on balance, promote or discourage
innovation.
In addition to these questions about the appropriate subject
matter of patent protection, the new technologies are also
challenging the traditional standards required for obtaining a
patent for an invention. These standards require that an
invention be new, useful, and nonobvious.12 In other words, it is
not enough that an invention be new; it must also be useful and
not the sort of innovation that would have been obvious to one
having ordinary skill in the particular “art” to which the
invention pertains. In the biotech field, in particular, both the
utility and the nonobviousness requirements seem to have been
increasingly watered down. Questions concerning utility are
particularly likely to arise with biotechnology inventions
“where patent claims to DNA fragments that an applicant has
shown to be functional genes or portions of genes but has not
yet determined what the specific function is.”13 Likewise,
CAFC case law seems to establish that a DNA sequence can be
non-obvious even though the information necessary for
isolating the sequence is publicly available.14 By statute, certain
biotech processes are deemed nonobvious if the process uses or
produces a new and nonobvious composition.15 These relaxed
requirements certainly promote upstream innovation but at
12. See 35 U.S.C. §§ 101-103 (1994).
13. 1 CHISUM ON PATENTS, supra note 6, § 4.02[2][g]; Rebecca S. Eisenberg & Robert P.
Merges, Opinion Letter as to the Patentability of Certain Inventions Associated with the
Identification of Partial cDNA Sequences, 23 AIPLA Q. J. 1, 3-20 (1995).
14. See, e.g., In re Deuel, 51 F.3d 1552, 1557-58 (Fed. Cir. 1995), discussed in Rai, supra
note 11, at 205-06.
15. See 35 U.S.C. § 103(b).
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what cost to downstream innovation?
As contentious as these questions are within the U.S., they
pale in comparison to the patent controversies that have arisen
in the international arena. Chronic North-South (i.e.
industrialized and developing world) divisions over the
appropriate scope of protection for patented inventions and for
intellectual property generally (i.e. patents, copyrights,
trademarks, and trade secrets) eventually contributed to the
establishment of the World Trade Organization (WTO), which
is vested with authority to implement and enforce the
provisions of the Agreement on Trade-Related Aspects of
Intellectual Property Rights, commonly called the TRIPS
Agreement. However, there are also growing “East-West”
divisions— as illustrated by recent political demonstrations that
began in Europe, protesting the importation of genetically
modified foods, but now, as a result of the abortive 1999 WTO
meeting held in Seattle, Washington,16 seem to be spreading to
this side of the Atlantic Ocean as well. Likewise, far more
concern has been expressed in Europe than has thus far
surfaced in the United States over the “morality” of patenting
living organisms.17
Meanwhile, on the other side of the Pacific, Japan’s patent
system, in marked contrast to that of the U.S., has historically
operated more for the benefit of users of the patent file (in
doing research and development) than patent owners.18 Many
16. Nuno Pires de Carvalho makes passing reference to this WTO meeting in the
introduction to his article. See Nuno Pires de Carvalho, Requiring Disclosure of the Origin of
Genetic Resources and Prior Informed Consent in Patent Applications Without Infringing the
TRIPS Agreement: The Problem and The Solution, 2 WASH. U. J.L. & POL’Y 371 (2000). For a
general discussion of emerging “East-West” conflicts in cyberspace, see Charles R. McManis,
Taking TRIPS on the Information Superhighway: International Intellectual Property Protection
and Emerging Computer Technology, 41 VILLANOVA L. REV. 207 (1996).
17. See, e.g. Cynthia M. Ho, Splicing Morality and Patent Law: Issues Arising from
Mixing Mice and Men, 2 WASH. U. J.L. & POL’Y 247 (2000).
18. See Samson Helfgott, Cultural Differences Between the U.S. and Japanese Patent
Systems, 72 J. PAT. [& TRADEMARK] OFF. SOC’Y 231 (1990); Toshiko Takenaka, The Role of
the Japanese Patent System in Japanese Industry, 13 UCLA PAC. BASIN L. J. 25 (1994). See
Washington University Open Scholarship
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Japanese applicants continue to file more for defensive
purposes— that is, to prevent anyone else from getting a patent
on a particular innovation— than to secure a patent for
themselves.19 While U.S. companies often complain that
Japanese patent protection is unduly weak, the reason is that the
intended beneficiary of the Japanese patent system has
historically been the user of the patent file, not the patent
holder. This is slowly changing, because both the U.S. and
Japanese patent systems are being amended to meet somewhere
in the middle, but this is resulting in as many changes in U.S. as
in Japanese patent law. For example, just last fall, U.S. patent
law was amended to provide that any domestic patent
application that is the subject of a foreign filing will henceforth
be publicized, or “laid open,” before the patent is actually
issued, thus possibly destroying any potential trade secret
protection before there is any guarantee that a patent will be
granted.20 Prompt publication of patent applications is the norm
in patent systems around the world, but the U.S. has historically
been more interested in protecting the confidentiality of the
application than in promoting prompt disclosure and public
scrutiny of the claimed invention. The original proposal to
publicize all U.S. patent applications prompted protest from
U.S. small businesses and individual inventors and eventually
necessitated retaining the confidentiality provision for
applicants who file only in the U.S. and not in other countries.
Among developing countries, on the other hand, there is
deep suspicion that strong intellectual property protection is
simply colonialism by other means— requiring developing
generally Dan Rosen & Chikako Usui, The Social Structure of Japanese Intellectual Property
Law, 13 UCLA PAC. BASIN L. J. 32 (1994). For recent developments in Japanese patent law,
however, see Toshiko Takenaka, Patent Infringement Damages in Japan and the United States:
Will Increased Patent Infringement Damage Awards Revive the Japanese Economy?, 2 WASH.
U. J.L. & POL’Y 309 (2000).
19. See Helfgott, supra note 18.
20. See Domestic Publication of Foreign Filed Patent Applications Act of 1999, Pub. L.
No. 106-113, 113 Stat. 1537-553, §§ 4501-4502 (1999).
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countries to pay for imported technology that they can ill-
afford. Developing countries also protest that the basic
premises of intellectual property protection are skewed in favor
of the industrialized world and against the essentially agrarian
developing world. A particularly “hot-button” topic in the
developing world is the issue of “biopiracy”— the practice of
researchers from industrialized countries to rely on traditional
knowledge of indigenous peoples to isolate promising biota that
becomes the basis for patent protection in the industrialized
world, without any compensation being given to the developing
country that maintains the traditional knowledge and the
relevant plant species for the benefit of the rest of the world.21
The patent policy issues at the heart of the foregoing
conflicts present a particularly timely symposium topic for the
recently re-engineered Washington University Journal of Law
and Policy. Not only is Washington University playing a key
role in the Human Genome Project and biomedical science
generally, it has also entered into a partnership with the
Missouri Botanical Garden, the Monsanto Company, and three
other mid-western universities to establish in St. Louis a new
$146 million Donald Danforth Plant Sciences Center, whose
first president is the noted plant scientist, Dr. Roger Beachy.22
Just within the last six months, St. Louis was the site of two
world renown botanical events— the first annual World
Agricultural Congress and the 16th International Botanical
Congress— evidence of the growing recognition that St. Louis
is becoming a leading center for biotechnology and plant
science research.23
21. See generally Charles R. McManis, The Interface Between International Intellectual
Property and Environmental Protection: Biodiversity and Biotechnology, 76 WASH. U. L. Q.
255 (1998). For a proposed response to this concern, see Carvalho, supra note 16.
22. See Liese Hutchison, Planting the Seeds: The St. Louis region has the potential to
become a world center for plant sciences, biotechnology and life sciences, ST. LOUIS COM.
MAG. (Oct. 1999); Vic Comello, Roger Beachy: A Leader in Revitalizing Plant Science, 41
CAHNERS R & D 18 (Oct. 1999).
23. See Richard C.D. Fleming, President and Chief Executive Officer, St. Louis Regional
Washington University Open Scholarship
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To capitalize on these developments, the School of Law at
Washington University has developed a strategic plan, entitled
“Building on Strength: Washington University School of Law
Strategic Plan (2000-2005),” which will concentrate on five
program areas of particular strength at the law school, including
interdisciplinary studies, international and comparative law
studies, and intellectual property and technology law studies.
By way of implementation, the School of Law recently
established two new academic centers— the Center for
Interdisciplinary Studies and the Institute for Global Legal
Studies. More recently still, the Dean of the Law School has
appointed an Intellectual Property Advisory Board to explore
the possibility of establishing an LLM and/or joint-degree
program in intellectual property and technology law. Co-
hosting (with the Bar Association of Metropolitan St. Louis) the
2000 Heart of America Patent Law and Policy Conference, held
at Washington University School of Law on March 31-April 1,
2000, and publishing the proceedings of that conference in the
Washington University Journal of Law & Policy, represents the
inaugural effort of the School of Law to contribute to the
ongoing interdisciplinary, international, and comparative
examination of the patent policy challenges posed by new
technologies.
In keeping with this overall approach to the topic of this
symposium, nine rising young patent law academics were asked
to present papers on a topic of their choice, the only specified
parameters being that they focus 1) on current patent policy
issues; 2) particularly those with an international, comparative,
or interdisciplinary dimension; and 3) more particularly still,
those policy issues that might relate to biotechnology law or the
life sciences. In response, these nine authors produced a wide
range of complementary papers that seemed to fall rather
Chamber and Growth Association, Commerce Comments, ST. LOUIS COM. MAG. (Oct. 1999).
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naturally into three overlapping clusters. Three of the papers
address particular administrative issues of patent policy
confronting the PTO; three papers address issues of judicial—
i.e. CAFC—  supervision of patent policy in the U.S.; and three
papers focus on international and/or comparative issues of
patent policy. Accordingly, the articles are grouped under these
three general headings. To underscore the importance of
international and comparative aspects of patent policy, the final
section of the symposium includes two supplemental articles in
addition to the three papers presented at the conference. The
first is an article by Dr. Nuno Pires de Carvalho, who is on the
staff of the World Intellectual Property Organization and served
as one of the three keynote speakers at the conference. The
second is an article by Professor Joseph Straus, Professor of
Law at the Universities of Ljubljana and Munich, and Head of
Department at the Max-Planck Institute for Foreign and
International Patent, Copyright and Competition Law, Munich.
Dr. Straus was to have been a paper presenter at the conference
but because of a schedule conflict was not able to attend.
However, he graciously allowed and secured permission for the
Washington University Journal of Law & Policy to publish a
slightly amended text of the Katz-Kiley Lecture which he gave
at the University of Houston Law Center on November 3, 1999.
A. Administrative Issues of Patent Policy
The first three articles in this symposium focus on
administrative patent policy issues confronting the PTO.
In the first article, “Patents as Incomplete Contracts:
Reducing the Information Asymmetry Between the Patentee
and the PTO,” Jay Kesan and Mark Banik propose viewing
patents as incomplete contracts that create contingent, or
probabilistic, property rights, where the probability of
invalidation reduces the expected return of a particular research
and development (R&D) investment, and thus diminishes the
Washington University Open Scholarship
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incentive to innovate. They point out that, because efficient
patent systems aim to induce investment in R&D, while
limiting social costs in the form of reduced levels of
competition or wasteful design-around efforts by competitors,
patent policy makers must consider not only the potential
distortions to perfect competition, but also a policy’s distortions
to incentives for investment in R&D. They then build on and
apply to the patent system Grossman and Hart’s economic
model of incomplete contracts and conclude that in the case of
high technology patents, where the PTO is poorly informed
about the relevant prior art, it may be optimal for the PTO to
provide incentives to the patentee to produce a complete prior
art disclosure by according a high presumption of validity to the
disclosed prior art, which would limit the use of the disclosed
prior art for invalidation purposes in subsequent (i.e., post-
issuance) litigation. Such a regime, they claim, would
maximize social welfare because it renders both the patentee
and the PTO (and hence, the public) better off. Such a policy
would induce the patent applicant to make higher levels of ex
ante investment in R&D, and with a fuller prior art disclosure
the PTO may be able to grant patent rights commensurate with
innovation and avoid the detrimental consequences of an
overbroad patent grant.
In the second article, “On Courts Herding Cats: Contending
with the ‘Written Description’ Requirement (and Other Unruly
Patent Disclosure Doctrine),” Mark Janis explores the problem
of incoherence in and among the three modern disclosure
requirements said to emanate from the first paragraph of section
112 of the U.S. patent statute— namely, the written description
of the invention requirement, the enabling disclosure
requirement (enabling any person skilled in the relevant art to
make and use the invention), and the best mode requirement
(setting forth the best mode contemplated by the inventor of
carrying out his invention). Specifically, Janis argues that the
distinction between the written description and enablement
https://openscholarship.wustl.edu/law_journal_law_policy/vol2/iss1/2
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requirements is artificial and that by perpetuating this
distinction the CAFC has impaired the development of a
coherent vision of the requirements for adequate disclosure,
devising instead an essentially standardless disclosure doctrine
that can be deployed arbitrarily, thus effectively arrogating to
itself unbridled authority to strike down claims for inadequate
disclosure. Janis goes on to examine the disclosure requirement
in comparative perspective, analyzing the jurisprudence of the
European Patent Office and the British patent system for
evidence of the same phenomenon whereby decisionmakers
reach beyond enablement for ill-defined ancillary disclosure
doctrines. He concludes with a brief analysis of why the written
description or analogous doctrines seem to proliferate
spontaneously on the landscape of patent disclosure
requirements and suggests that courts instead consider more
carefully whether the enabling disclosure requirement is in fact
being applied to require an enabling disclosure that correlates to
the scope of the patent claims.
In the third article, “On Improving the Legal Process of
Patent Claim Interpretation,” John Duffy points out that,
although many commentators have addressed the issue of claim
interpretation, few have studied in depth the allocation of
interpretative power among the legal actors in the patent
system. The focus has been on the “how” of claim
interpretation, not the “who.” As Duffy points out, however,
technological progress is inextricably intertwined with the
advancement of the legal and social norms by which society
organizes itself. Building on Williamson’s observation that “the
study of organizational innovation has never been more than a
poor second cousin to the study of technological innovation,”
Duffy proposes to examine the process of patent claim
interpretation by a method that parallels methods of
technological innovation. Thus, in addition to reassessing a
particular doctrinal area of patent law, his article is also a study,
or experiment, in method: He employs the method of an
Washington University Open Scholarship
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innovator to seek insight into a discrete but significant part of
the legal process of innovation. In part I of his article, Duffy
defines the particular legal problem to be addressed. By treating
claim interpretation as a pure issue of law subject to de novo
review on appeal, the case law has centralized claim
interpretation in the Federal Circuit. While that makes for
uniformity, it can also lead to dramatic procedural
inefficiencies of precisely the sort that Kesan and Banik say
reduces the value of patent rights and thus the incentive to
innovate. The challenge, according to Duffy, is to reduce the
inefficiency without sacrificing uniformity. In part II of his
article, Duffy provides a “Winslow Tableau,” invoking In re
Winslow’s image of the inventor “working in his shop with the
prior art references . . . hang on the walls around him,” in order
to offer a similar compendium of “the relevant prior art” for
analyzing and resolving the technical legal problem introduced
in part I. The tableau goes beyond American patent law to
identify possible solutions both from other branches of
domestic law and the patent law of other jurisdictions, focusing
primarily on what Duffy calls “primary jurisdiction and
administrative claim interpretation.” Finally, in part III, having
noted that developing market-like mechanisms to test a legal
technology may itself be an accomplishment of great ingenuity,
Duffy discusses one such mechanism and its application to the
procedural innovation introduced in part II of his article.
II. JUDICIAL ISSUES OF PATENT POLICY
The second three articles in the symposium focus on CAFC
supervision of patent policy in the U.S.
In the first article, “Strangers in a Strange Land:
Biotechnology and the Federal Circuit,” Lawrence Sung, who
holds a Ph.D. in microbiology as well as a law degree, surveys
the recent CAFC biotechnology decisions from the combined
perspective of science and the law. As he notes, while the
https://openscholarship.wustl.edu/law_journal_law_policy/vol2/iss1/2
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casual observer might attribute the seeming incongruity
between the jurisprudence of the CAFC and the underlying
scientific realities to the absence of judges on the court who
may be said to exemplify the hypothetical person of ordinary
skill in the art, the perceived incongruity might also be the
result of the scientific community’s ignorance of the procedural
guidelines and substantive legal precedent to which the court
must remain faithful in rendering its judgments. In particular,
Sung notes the general failure to appreciate a significant
temporal distortion in the court’s biotechnology decisions.
Much like an astronomer peering into the heavens, the CAFC in
its biotechnology decisions not only confronts almost
unfathomable complexity; it is also looking back in time. Given
that backward temporal distortion, Sung wonders what
meaningful guidance the court can provide for today’s realities
and tomorrow’s possibilities. Still, as Sung goes on to
demonstrate, the CAFC’s recent biotechnology decisions
provide a glimpse of the fundamental patent-law principles to
which the court will likely continue to adhere. In part I of his
article, Sung examines those cases in which the statutory
conditions for patentability and the disclosure requirements are
implicated. The requirements of utility, nonobviousness,
written description, and enablement take center state here. In
part II, Sung examines issues of inventorship and priority of
invention. In part III, he reviews biotechnology litigation at
both the administrative and judicial levels, focusing on
interference proceedings before the PTO and patent
infringement actions before the federal courts.
In the second article, “Addressing the Patent Gold Rush:
Deference to PTO Patent Denials,” Arti Rai observes that, even
for those who would rather do so, it is difficult to ignore the
headlong rush to claim patent rights in the two dynamic, rapidly
evolving industries that undergird the information economy—
namely, biotechnology and computer technology. She goes on
to make three basic points. First, she identifies the factors that
Washington University Open Scholarship
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have led to the current spate of patent filings and argues that the
evidence points squarely towards certain questionable CAFC
decisions reversing PTO denials of patent protection to various
biotechnology and computer program inventions as a major
reason for the recent proliferation of high technology patents.
Second, she stresses the importance of CAFC deference with
respect to PTO determinations concerning nonobviousness,
noting that although the PTO may well operate under a skewed
set of incentives as well as limitations on its own resources and
expertise, these incentives and limitations will tend
systematically to produce errors in patent grants, not patent
denials. Finally, she discusses the administrative law doctrines
through which greater CAFC deference to the PTO should be
implemented, arguing that the starting point must be the
Supreme Court’s seminal decision in Chevron v. Natural
Resources Defense Council.
In the third article, “Patents and Cumulative Innovation,”
Clarisa Long addresses the widespread concern that granting
proprietary rights to basic research results will hamper the
progress of science, stifle the flow of new knowledge and the
dissemination of research results, and chill the research efforts
of scientists who fear infringement liability. She begins by
noting that the discussion of the proper role of proprietary
rights in general and patents in particular has long been
dominated by models that apply a linear approach to the
process of scientific discovery and innovation, which assume
that a patented product is the final consumer end product.
However, scientific research— and particularly biomedical
research— is not linear and is in any event undergoing a
paradigmatic shift as biomedical research is becoming
increasingly information based; as basic research and product
development increasingly depend on non-linear, continuous
interactions with each other; and as scientific practices and
industry business models evolve to blur traditional boundaries
between public and private goods. Whereas traditional
https://openscholarship.wustl.edu/law_journal_law_policy/vol2/iss1/2
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pharmaceutical innovation tended to be a capital-intensive,
high-risk process, which benefited from strong patent
protection on the product that finally emerged at the end of the
research pipeline, biomedical research, particularly that
pertaining to genomics, departs from this model. Genomic
information and information-based research tools have
themselves become marketable. New entrants in the upstream
market for genomic information are less capital intensive,
exhibit much faster time to market, and offer different risk-
reward models for investors than the traditional pharmaceutical
companies. According to Long, the link between scientific
breakthroughs and marketable innovations continues to shorten
and tighten. In such an environment, she argues, it is unclear
whether conclusions gleaned from industries characterized by
tangible commercial products can be extrapolated to biomedical
research generally, but she believes it to be certain that such
conclusions cannot be extended to patents on biomedical
research results that are so far upstream that no commercial
product currently exists. She concludes that there is at present
no clear analytical answer to the question of how to distribute
the incentives between basic researchers and downstream
innovators so as to optimize innovation at all stages of the
research and development process. She believes that in all
likelihood, the answer will differ from industry to industry and
from scientific field to scientific field. What is clear is that we
must revamp our models of proprietary rights to reflect the
research environment accurately and to create the optimum
incentive for scientific innovation.
III. INTERNATIONAL AND COMPARATIVE LAW ISSUES OF PATENT
POLICY
The final three articles, supplemented by the articles of Dr.
Carvalho and Professor Straus, concentrate on international and
comparative issues of patent law and policy.
Washington University Open Scholarship
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In her article, “Splicing Morality and Patent Law: Issues
Arising from Mixing Mice and Men,” Cynthia Ho begins by
describing how the long-dormant issue of “moral utility” was
recently (and dramatically) resurrected by the filing of a patent
application claiming “chimeric embryos” containing both
human and non-human cells— a filing designed to engender
discussion and debate on precisely that obscure patent issue.
The strategy of the applicants was evidently successful, because
it prompted the PTO to issue a “media advisory” on the subject
and led then PTO Commissioner Bruce Lehman to state
publicly that “there will be no patents on monsters, at least not
while I’m commissioner.” Ho’s article seeks to advance this
discussion by examining existing models for incorporating
ethics into the determination of patentability, particularly those
developed in Europe for excluding patents on the basis of ethics
and morality. In part II of her article, Ho discusses the
prohibition contained in article 53(a) of the European Patent
Convention (EPC) and its application in four specific cases. In
part III, she discusses how article 6(2) of the EU Directive on
Biotechnology might be applied in the case of the U.S.
“chimeric embryos” application. Ho concludes that, despite
substantial consideration of the issue, the EU was unable to
arrive at a formulation that is any more effective than the
original system under the EPC— and in some ways its
formulation may in fact be less preferable. In the end, she
doubts whether the game is worth the candle. Instead of using
the patent system to address controversial issues concerning the
morality of certain lines of research, Ho believes that these
issues should be addressed through a more direct approach
regulating the research itself.
As indicated by the title of his article, “Contributory
Infringement of Patents in Korea,” Sang-Jo Jong discusses the
Korean doctrine of contributory infringement, as it was applied
(or in Professor Jong’s judgment, misapplied) by the Korean
Supreme Court in the 1996 case of Samsung Electronics, Inc. v.
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Sung-kyo Cho. Jong’s analysis of the case graphically illustrates
how difficult it can be for the legislature and judicial system of
a newly industrialized country, having only limited experience
with patent legislation and enforcement, to grasp or articulate
all of the nuances of a doctrine that required almost a century of
judicial development in the U.S. before being codified. The
experience of the Republic of Korea— which is viewed by
many as a model to be followed by the developing world—
serves as a cautionary tale for anyone who naively expects that
implementation of the 1994 Agreement on Trade Related
Aspects of Intellectual Property Rights (better known as the
TRIPS Agreement) will necessarily result in a rapid, or
salutary, transplantation of patent law in the developing world,
or even in the newly industrialized world, where the endeavor
stands the best chance of success.
By way of instructive comparison, Toshiko Takenaka, in her
article, “Patent Infringement Damages in Japan and the United
States: Will Increased Patent Infringement Damage Awards
Help Revive the Japanese Economy?,” points out that the
Japanese government, in looking for ways to revive the
Japanese economy, has become convinced that U.S. patent
policy and other legislation designed to encourage technology
transfer are among the primary reasons that the U.S. recovered
from its most recent recession so much more quickly than
Japan. In April, 1997 a government sponsored commission, the
Commission on Intellectual Property Rights in the Twenty-First
Century, published a report emphasizing the need to strengthen
intellectual property rights in Japan in order to promote
development of breakthrough technologies. The report has
prompted major changes in Japanese patent policy at all
levels— administrative, judicial and legislative— culminating
with a revision of the patent law provisions relating to patent
enforcement procedures and the calculation of damages for
infringement. In her paper, Takenaka examines the impact of
the new legislation governing patent damages and discusses
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whether the increase in damage awards contributes to the
creation of breakthrough technology. Part I of her article
discusses the pre-1998 law governing patent damages and
highlights the differences between U.S. and Japanese practice
by comparing specific case examples. Part II of her article
focuses on a particular case, SmithKline & Beecham French
Laboratories Ltd. v. Fujimoto Seiyaku, decided under the 1998
amendments, in which the Tokyo District Court awarded the
plaintiff $23.5 million in lost profits in a case in which a
Japanese generic drug manufacturer had imported the product
of the allegedly infringed process from Slovenia and sold it in
Japan. In part III of her article, Takenaka addresses the question
of whether these changes in Japanese patent law will achieve
their policy objectives and concludes that the increased damage
awards create a risk of overcompensation, but that, despite this
risk, they may well encourage investment in technology and
assist in the establishment of start-ups and spin-offs based on
new technologies.
In his article “Patent Litigation in Europe— A Glimmer of
Hope? Present Status and Future Perspectives,” Joseph Straus
provides a comprehensive overview of the present status of
patent litigation in Europe, particularly as it compares with
other efforts to achieve economic and legal integration in
Europe. While not yet a reality, there is, he says, a glimmer of
hope that Europe will adopt an integrated system for litigating
European patents within the foreseeable future.
Finally, Dr. Nuno Carvalho, in his paper “Requiring
Disclosure of the Origin of Genetic Resources and Prior
Informed Consent in Patent Applications without Infringing the
TRIPS Agreement: the Problem and the Solution,” discusses a
patent policy issue that was initially stimulated by the
Convention on Biological Diversity, which was opened for
signature on June 5, 1992, at the United Nations Conference on
the Environment and Development (the Rio “Earth Summit”).
What is at stake, he says, is the possibility of detecting
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commercial gains from the use of genetic resources so that
countries supplying those resources can demand their share of
the benefits. Dr. Carvalho first describes how the requirement
that the origin of genetic resources and prior informed consent
be disclosed in patent applications has been raised by different
countries in at least two different international fora— namely
the World Trade Organization (WTO)(before the Council for
TRIPS and the General Council) and the World Intellectual
Property Organization (WIPO)(before the Standing Committee
on Patents). Then he discusses how such a requirement might
conflict with the WTO TRIPS Agreement. Finally, he suggests
a practical solution to the problem, indicating how such a
requirement might be incorporated into nation, regional, or
international law without conflicting with TRIPS.
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